Your session is about to expire
← Back to Search
ERAS-601 for Advanced Solid Cancer (FLAGSHP-1 Trial)
FLAGSHP-1 Trial Summary
This trial is testing the safety and effectiveness of a new drug, ERAS-601, for treating advanced or metastatic solid tumors.
FLAGSHP-1 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowFLAGSHP-1 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.FLAGSHP-1 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been treated with a SHP2 inhibitor before.I have brain cancer or cancer that has spread to my brain.I received radiation to ease symptoms within the last week.I can't use standard cancer treatments due to side effects, ineffectiveness, or access issues.I am fully active or can carry out light work.My cancer is advanced or has spread and confirmed by lab tests.I have had stomach surgery or a condition that affects how drugs are absorbed in my body.My cancer has a PTPN11 mutation.I haven't had a stroke or blood clot in the last 3 months.I have a serious lung condition that is not under control.My heart, blood, liver, and kidneys are all functioning well.I can take pills by mouth.I am 18 years old or older.I have or am at risk for blocked veins in my eye.
- Group 1: Dose Escalation (Part A): ERAS-601 monotherapy
- Group 2: Dose Escalation (Part B): ERAS-601 monotherapy
- Group 3: Dose Escalation (Part C): ERAS-601 monotherapy
- Group 4: Dose Escalation and Dose Expansion (Part D): ERAS-601 in combination with cetuximab
- Group 5: Dose Escalation and Dose Expansion (Part E): ERAS-601 in combination with pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the aggregate quantity of participants in this research?
"Affirmative. The information on clinicaltrials.gov suggests that this medical study is currently seeking participants, and was first posted to the website on December 15th 2020, with its most recent update occurring November 16th 2022. 200 patients are needed from 8 different sites for enrolment in total."
What are the safety implications for those using ERAS-601?
"ERAS-601 safety was judged to be a 1 on the scale of 1 to 3 due to the limited data available, indicating it is in Phase 1 of clinical trials."
Are younger individuals aged 45 or under eligible to join this research project?
"This medical trial requires that participants are aged 18 to 99 years old. However, if you fall outside of this age range there are 303 studies for those under the age of consent and 2324 trials targeting individuals over 65."
In how many venues is this research endeavor being conducted?
"The study is active in 8 locations, such as the Comprehensive Cancer Center of Nevada (Henderson), Sarah Cannon Research Institute (Tennessee Oncology; Nashville) and The University of Texas MD Anderson Cancer Centre (Houston). Several other facilities are also included."
Are there any additional reports on the use of ERAS-601?
"Currently, 121 underway studies have been conducted on ERAS-601 with 30 trials in the Phase 3 stage. Most of these are happening out of Dresden, Arizona; however, there are 5333 other locations running their own research into ERAS-601."
What purpose is ERAS-601 typically employed for?
"ERAS-601 is applied to manage pharmacotherapy, as well as regionally advanced squamous cell carcinoma of the head and neck (hnscc), metastatic squamous cell carcinoma of the head and neck, and general squamous cell carcinoma."
Are there any vacancies for participation in this trial?
"Clinicaltrials.gov has confirmed that this clinical trial is actively looking for participants, with the initial post being made on December 15th 2020 and most recent edit occurring on November 16th 2022."
Share this study with friends
Copy Link
Messenger